JP2005528099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528099A5 JP2005528099A5 JP2004508275A JP2004508275A JP2005528099A5 JP 2005528099 A5 JP2005528099 A5 JP 2005528099A5 JP 2004508275 A JP2004508275 A JP 2004508275A JP 2004508275 A JP2004508275 A JP 2004508275A JP 2005528099 A5 JP2005528099 A5 JP 2005528099A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- light chain
- variable domain
- domain sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004408 hybridoma Anatomy 0.000 claims 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 102400000401 Latency-associated peptide Human genes 0.000 claims 4
- 101800001155 Latency-associated peptide Proteins 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 101100274557 Heterodera glycines CLE1 gene Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000024985 Alport syndrome Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000003215 hereditary nephritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36499102P | 2002-03-13 | 2002-03-13 | |
| US42628602P | 2002-11-13 | 2002-11-13 | |
| PCT/US2003/008048 WO2003100033A2 (en) | 2002-03-13 | 2003-03-13 | ANTI-αvβ6 ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009011451A Division JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αｖβ６抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005528099A JP2005528099A (ja) | 2005-09-22 |
| JP2005528099A5 true JP2005528099A5 (https=) | 2006-04-27 |
| JP4473117B2 JP4473117B2 (ja) | 2010-06-02 |
Family
ID=29586753
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508275A Expired - Fee Related JP4473117B2 (ja) | 2002-03-13 | 2003-03-13 | 抗αｖβ６抗体 |
| JP2009011451A Withdrawn JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αｖβ６抗体 |
| JP2012177348A Expired - Lifetime JP5616932B2 (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2012177349A Withdrawn JP2012228269A (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2014234208A Withdrawn JP2015091807A (ja) | 2002-03-13 | 2014-11-19 | 抗αｖβ６抗体 |
| JP2015048289A Withdrawn JP2015126743A (ja) | 2002-03-13 | 2015-03-11 | 抗αｖβ６抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009011451A Withdrawn JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αｖβ６抗体 |
| JP2012177348A Expired - Lifetime JP5616932B2 (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2012177349A Withdrawn JP2012228269A (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2014234208A Withdrawn JP2015091807A (ja) | 2002-03-13 | 2014-11-19 | 抗αｖβ６抗体 |
| JP2015048289A Withdrawn JP2015126743A (ja) | 2002-03-13 | 2015-03-11 | 抗αｖβ６抗体 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7465449B2 (https=) |
| EP (4) | EP2287198A3 (https=) |
| JP (6) | JP4473117B2 (https=) |
| KR (1) | KR101098109B1 (https=) |
| CN (4) | CN104805090A (https=) |
| AR (1) | AR038970A1 (https=) |
| AU (1) | AU2003261071C1 (https=) |
| BR (1) | BRPI0308585B8 (https=) |
| CA (1) | CA2478833C (https=) |
| CL (8) | CL2010000790A1 (https=) |
| EA (1) | EA011853B1 (https=) |
| ES (1) | ES2389037T3 (https=) |
| HK (1) | HK1213007A1 (https=) |
| IL (4) | IL164021A0 (https=) |
| IS (1) | IS7443A (https=) |
| ME (1) | ME00804B (https=) |
| MX (1) | MXPA04008870A (https=) |
| MY (2) | MY154009A (https=) |
| NO (1) | NO334834B1 (https=) |
| NZ (2) | NZ535425A (https=) |
| PL (1) | PL216223B1 (https=) |
| RS (1) | RS52488B (https=) |
| WO (1) | WO2003100033A2 (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ535425A (en) * | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| CA2481922A1 (en) * | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| CA2434668A1 (en) | 2003-07-04 | 2005-01-04 | Laurence Mulard | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
| AU2012258386B2 (en) * | 2005-07-08 | 2014-08-07 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| WO2007084570A2 (en) * | 2006-01-17 | 2007-07-26 | Biosite Incorporated | High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis |
| CN101563105B (zh) * | 2006-07-10 | 2013-01-23 | 拜奥根Idec马萨诸塞公司 | 用于抑制smad4-缺陷癌症的组合物和方法 |
| EP2064244B1 (en) * | 2006-08-03 | 2019-06-05 | MedImmune Limited | ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF |
| JP2010506944A (ja) * | 2006-10-19 | 2010-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防 |
| US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| ES2585702T3 (es) * | 2007-05-30 | 2016-10-07 | Lpath, Inc | Composiciones y métodos para la unión al ácido lisofosfatídico |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| EP2207568B1 (en) * | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| CN102083859B (zh) | 2008-05-07 | 2014-09-17 | 阿哥斯医疗公司 | 人源化抗人干扰素-α抗体 |
| CA2723842A1 (en) * | 2008-05-09 | 2009-11-12 | Peter Vanlandschoot | Amino acid sequences directed against integrins and uses thereof |
| JP2011523551A (ja) * | 2008-05-15 | 2011-08-18 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 血管形成の調節の新規ターゲット |
| US8552154B2 (en) * | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| CN102597001B (zh) * | 2009-08-19 | 2014-07-30 | 默克专利有限公司 | 在ffpe材料中用于检测整联蛋白复合体的抗体 |
| WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| MX340696B (es) * | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anticuerpos anti-c5a y metodos para usar los anticuerpos. |
| BR112013027119A8 (pt) | 2011-04-21 | 2018-03-06 | Seattle Genetics Inc | novos conjugados ligante-droga (adcs) e uso dos mesmos |
| US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
| SG11201404354UA (en) * | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| EP2900265B1 (en) | 2012-09-27 | 2018-05-30 | Biocare Medical, LLC | Anti-uroplakin ii antibodies systems and methods |
| WO2014054820A1 (ja) * | 2012-10-03 | 2014-04-10 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| DK2962113T3 (da) | 2013-02-28 | 2019-07-01 | Biocare Medical Llc | Systemer og fremgangsmåder med anti-p40-antistoffer |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| WO2014143739A2 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| WO2014144466A1 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| CN113150145B (zh) | 2013-08-30 | 2025-02-14 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| KR102150616B1 (ko) | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
| CA2925057A1 (en) * | 2013-10-01 | 2015-04-09 | Simon T. BARRY | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| US9816997B2 (en) | 2013-10-03 | 2017-11-14 | Biocare Medical, Llc | Anti-SOX10 antibody systems and methods |
| CN104721225A (zh) | 2013-12-19 | 2015-06-24 | 高露洁-棕榄公司 | 口腔护理组合物 |
| RU2698697C2 (ru) | 2013-12-23 | 2019-08-29 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего (ADC) с ингибиторами KSP |
| US20170008955A1 (en) * | 2014-02-03 | 2017-01-12 | Cnj Holdings, Inc. | Humanized beta-amyloid binding molecules and uses thereof |
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| EP3313523A2 (en) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of ksp inhibitors |
| WO2017027685A2 (en) * | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
| CN116440279B (zh) | 2015-09-17 | 2026-02-24 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| HK1254295A1 (zh) * | 2015-11-23 | 2019-07-19 | 默克专利股份有限公司 | 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体 |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| US20190284259A1 (en) * | 2016-07-22 | 2019-09-19 | Georgia State University Research Foundation | Monoclonal Antibodies to B Virus And Their Use For Identification Of B Virus Specific Reactive Peptides |
| EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| CN110198718B (zh) | 2016-11-08 | 2023-01-10 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法 |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20200253506A1 (en) | 2016-12-14 | 2020-08-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| CN110312534B (zh) | 2016-12-21 | 2023-04-04 | 拜耳制药股份公司 | 具有酶促可裂解基团的抗体-药物-缀合物(adc) |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| GB201720989D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| BR112020022961A2 (pt) | 2018-05-11 | 2021-02-17 | Glaxosmithkline Intellectual Property Development Limited | inibidores de furina |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| KR20220005471A (ko) * | 2019-04-08 | 2022-01-13 | 바이오젠 엠에이 인코포레이티드 | 항-인테그린 항체 및 이의 용도 |
| GB201908536D0 (en) | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
| WO2021108302A1 (en) * | 2019-11-26 | 2021-06-03 | Children's Hospital Medical Center | Cela-1 inhibition for treatment of lung disease |
| US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| JP2024505001A (ja) * | 2021-01-26 | 2024-02-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ａｖｂ８インテグリンに関連する疾患を処置および予防するための組成物および方法 |
| CN117222410A (zh) | 2021-02-03 | 2023-12-12 | Bp资产V股份有限公司 | 用于吸入的弗林蛋白酶抑制剂的制剂 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
| EP4731670A2 (en) | 2023-06-23 | 2026-04-29 | Mythic Therapeutics, Inc. | Ph sensitive anti-itgb6 antibodies and uses thereof |
| AU2024346987A1 (en) | 2023-09-19 | 2026-04-02 | Telix Targeting Technologies, Inc. | Antigen binding constructs |
| WO2025163120A1 (en) | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
| WO2026012032A1 (en) * | 2024-07-10 | 2026-01-15 | Wuxi Biologics (Shanghai) Co., Ltd. | Antibodies against integrin and uses thereof |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US5223493A (en) | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5804381A (en) * | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6417324B1 (en) * | 2000-04-21 | 2002-07-09 | Tripep Ab | Synthetic peptides that bind to the hepatitis B virus core and e antigens |
| EP0719859B1 (en) * | 1994-12-20 | 2003-07-02 | MERCK PATENT GmbH | Anti-alpha V-integrin monoclonal antibody |
| US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ATE265861T1 (de) | 1995-08-17 | 2004-05-15 | Protein Design Labs Inc | Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| KR100308764B1 (ko) | 1995-08-29 | 2001-12-17 | 마나배게이사꾸 | 키메라동물및그의제작법 |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| CA2257357C (en) * | 1996-06-07 | 2010-04-13 | Neorx Corporation | Humanized antibodies with modified glycosylation |
| WO1998006839A1 (en) | 1996-07-15 | 1998-02-19 | Human Genome Sciences, Inc. | Cd44-like protein |
| US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
| ATE511850T1 (de) * | 1997-08-08 | 2011-06-15 | Univ California | Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin |
| BR9907218A (pt) * | 1998-01-23 | 2000-10-24 | Merck Patent Gmbh | Anticorpo monoclonal anti alfav-integrina e seu uso para inibir a fixação de alfav-beta6-integrina à fibronectina |
| CZ20012212A3 (cs) | 1998-12-19 | 2001-09-12 | Merck Patent Gmbh | Peptidická sloučenina, její použití a farmaceutický prostředek, který ji obsahuje |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| DE10063173A1 (de) | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
| DE60236735D1 (de) | 2001-04-13 | 2010-07-29 | Biogen Idec Inc | Antikörper gegen vla-1 |
| DE10118550A1 (de) | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
| GB2380127A (en) | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
| DK1485127T3 (da) | 2002-02-25 | 2011-10-03 | Elan Pharm Inc | Anvendelse af midler til behandling af inflammation |
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| CA2481922A1 (en) | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| JP4741242B2 (ja) | 2002-11-26 | 2011-08-03 | アボット バイオセラピューティクス コーポレイション | 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体 |
| US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| ATE399542T1 (de) | 2003-10-01 | 2008-07-15 | Merck Patent Gmbh | Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel |
| ES2343840T3 (es) | 2003-11-04 | 2010-08-11 | Bayer Healthcare Llc | Procedimientos inmunohistoquimicos para supervisar los niveles de perk. |
| CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| CN101563105B (zh) | 2006-07-10 | 2013-01-23 | 拜奥根Idec马萨诸塞公司 | 用于抑制smad4-缺陷癌症的组合物和方法 |
| JP2010506944A (ja) | 2006-10-19 | 2010-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防 |
| GB0803192D0 (en) | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
| EP2706358A3 (en) | 2008-12-23 | 2014-05-07 | Merck Patent GmbH | Biomarkers for inhibitors with anti-angiogenic activity |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| HK1208470A1 (en) | 2012-03-29 | 2016-03-04 | Biogen Ma Inc. | Biomarkers for use in integrin therapy applications |
-
2003
- 2003-03-13 NZ NZ535425A patent/NZ535425A/en not_active IP Right Cessation
- 2003-03-13 AU AU2003261071A patent/AU2003261071C1/en not_active Expired
- 2003-03-13 CN CN201510182148.6A patent/CN104805090A/zh active Pending
- 2003-03-13 CN CN2012100664380A patent/CN102659946A/zh active Pending
- 2003-03-13 CN CN201210067222.6A patent/CN102924598B/zh not_active Expired - Lifetime
- 2003-03-13 MY MYPI20094390A patent/MY154009A/en unknown
- 2003-03-13 EP EP10013155A patent/EP2287198A3/en not_active Ceased
- 2003-03-13 EP EP10013156.4A patent/EP2287199B1/en not_active Expired - Lifetime
- 2003-03-13 ME MEP-2009-200A patent/ME00804B/me unknown
- 2003-03-13 EA EA200401198A patent/EA011853B1/ru unknown
- 2003-03-13 EP EP03755325A patent/EP1490110B1/en not_active Expired - Lifetime
- 2003-03-13 PL PL372662A patent/PL216223B1/pl unknown
- 2003-03-13 AR ARP030100885A patent/AR038970A1/es not_active Application Discontinuation
- 2003-03-13 JP JP2004508275A patent/JP4473117B2/ja not_active Expired - Fee Related
- 2003-03-13 RS YU80704A patent/RS52488B/sr unknown
- 2003-03-13 KR KR1020047014307A patent/KR101098109B1/ko not_active Expired - Lifetime
- 2003-03-13 WO PCT/US2003/008048 patent/WO2003100033A2/en not_active Ceased
- 2003-03-13 MX MXPA04008870A patent/MXPA04008870A/es active IP Right Grant
- 2003-03-13 ES ES03755325T patent/ES2389037T3/es not_active Expired - Lifetime
- 2003-03-13 US US10/507,662 patent/US7465449B2/en not_active Expired - Lifetime
- 2003-03-13 CN CNA038089068A patent/CN1646160A/zh active Pending
- 2003-03-13 EP EP10012545A patent/EP2336185A1/en not_active Withdrawn
- 2003-03-13 CA CA2478833A patent/CA2478833C/en not_active Expired - Lifetime
- 2003-03-13 MY MYPI20030886A patent/MY147019A/en unknown
- 2003-03-13 IL IL16402103A patent/IL164021A0/xx unknown
- 2003-03-13 BR BRPI0308585A patent/BRPI0308585B8/pt not_active IP Right Cessation
- 2003-12-13 NZ NZ563951A patent/NZ563951A/en not_active IP Right Cessation
-
2004
- 2004-09-09 IS IS7443A patent/IS7443A/is unknown
- 2004-09-12 IL IL164021A patent/IL164021A/en active IP Right Grant
- 2004-09-12 IL IL225633A patent/IL225633B/en unknown
- 2004-10-13 NO NO20044347A patent/NO334834B1/no not_active IP Right Cessation
-
2008
- 2008-10-29 US US12/260,510 patent/US8153126B2/en not_active Expired - Lifetime
-
2009
- 2009-01-21 JP JP2009011451A patent/JP2009100763A/ja not_active Withdrawn
-
2010
- 2010-07-23 CL CL2010000790A patent/CL2010000790A1/es unknown
- 2010-07-23 CL CL2010000789A patent/CL2010000789A1/es unknown
- 2010-07-23 CL CL2010000787A patent/CL2010000787A1/es unknown
- 2010-07-23 CL CL2010000792A patent/CL2010000792A1/es unknown
- 2010-07-23 CL CL2010000788A patent/CL2010000788A1/es unknown
- 2010-07-23 CL CL2010000785A patent/CL2010000785A1/es unknown
- 2010-07-23 CL CL2010000786A patent/CL2010000786A1/es unknown
- 2010-07-23 CL CL2010000791A patent/CL2010000791A1/es unknown
-
2012
- 2012-04-10 US US13/443,261 patent/US20120251532A1/en not_active Abandoned
- 2012-08-09 JP JP2012177348A patent/JP5616932B2/ja not_active Expired - Lifetime
- 2012-08-09 JP JP2012177349A patent/JP2012228269A/ja not_active Withdrawn
-
2013
- 2013-04-08 IL IL225633A patent/IL225633A0/en unknown
-
2014
- 2014-07-28 US US14/444,701 patent/US9745376B2/en not_active Expired - Fee Related
- 2014-11-19 JP JP2014234208A patent/JP2015091807A/ja not_active Withdrawn
-
2015
- 2015-03-11 JP JP2015048289A patent/JP2015126743A/ja not_active Withdrawn
-
2016
- 2016-01-22 HK HK16100767.3A patent/HK1213007A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005528099A5 (https=) | ||
| ME00804B (me) | Anti-alpha v beta 6 antitela | |
| JP2009541204A5 (https=) | ||
| JP2007536932A5 (https=) | ||
| JP2022079549A5 (https=) | ||
| JP2004517611A5 (https=) | ||
| JP2010523096A5 (https=) | ||
| JP2009517057A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| RU2009101788A (ru) | Направленные на опухоль моноклональные антитела против fzd10 и их применение | |
| JP2005533493A5 (https=) | ||
| JP2005225884A5 (https=) | ||
| JP2021526022A5 (https=) | ||
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| JP2019107018A5 (https=) | ||
| JP2022530404A5 (https=) | ||
| JP2008529497A5 (https=) | ||
| JP2020526478A5 (https=) | ||
| JP2021531254A5 (https=) | ||
| JP2005538701A5 (https=) | ||
| JP2010533498A5 (https=) | ||
| JP2010501164A5 (https=) | ||
| JP2006507013A5 (https=) | ||
| ME02581B (me) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| JP2011528561A5 (https=) |